Gå till innehåll

Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal



Hazard - P - B - T - Risk See below


Risk. See below.

Assessment report

Assessment report for Aimovig (erenumab) 31 May 2018 EMA/CHMP/413393/2018.

"Monoclonal antibodies such as AMG 334 (erenumab ed. remark) are catabolized to individual amino acids and/or small peptides by endogenous proteases and high molecular weight prevents intact urinary excretion. As such, excretion of active drug is not expected. For these reasons, exposure to concentrations of AMG 334 in the environment does not pose any concern."

Fass environmental information

Environmental information for erenumab is not available on Fass.se (2020-10-06). It is voluntary for manufacturers to publish environmental impact information on Fass.se.

Author: Health and Medical Care Administration, Region Stockholm